Cumberland Q3 revenue up 41% to $11.4M; net loss narrows to $0.4M

CUMBERLAND PHARMACEUTICALS INC

2022-Q3 EPS reported -$0.21 revenue$11,413,072

Net revenue $11.4M vs $8.1M a year ago, driven by Sancuso ($4.0M) and Kristalose ($3.9M).
Net loss improved to $0.4M from $1.1M; adjusted earnings $1.4M ($0.10/share).
Year-to-date cash from operations $5.6M, up 28% from $4.4M.
Completed Sancuso transition under co-promotion with Verity; RediTrex amendment allows Nordic to assume U.S. commercialization after March 2023.
Phase II ifetroban trials ongoing; AERD study closed to enrollment awaiting top-line results.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

CUMBERLAND PHARMACEUTICALS INC reported the three months ended September 30, 2022 results: revenue $11.4 million, net income Net loss for the third quarter of 2022 was $0.4 million.

Period: the three months ended September 30, 2022
Revenue: $11.4 million
Net income: Net loss for the third quarter of 2022 was $0.4 million
Result: reported results

Exact text from the filing

Pharmaceuticals Inc. (NASDAQ: CPIX) , a specialty pharmaceutical company, announced today that its product portfolio of FDA-approved brands delivered combined revenues of $11.4 million during the third quarter of 2022 - a 41% increase over the prior year period. Cumberland also reported a 19% increase in net revenues for the first nine months of the year

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

CUMBERLAND PHARMACEUTICALS INC reported the nine months ended September 30, 2022 results: revenue $33 million.

Period: the nine months ended September 30, 2022
Revenue: $33 million
Result: reported results

Exact text from the filing

of 2022, included $4.0 million for Sancuso ® , $3.9 million for Kristalose ® , $1.9 million for Vibativ ® and $0.9 million for Caldolor ® . Year-to-date 2022 net revenues were $33 million, a 19% increase compared to $28 million for the first nine months of 2021. Year-to-date net revenues by product were $11.4 million for Kristalose, $10.8 million for Sancuso, $6.0

View on SEC.gov

Browse all earnings releases →

CUMBERLAND PHARMACEUTICALS INC filing history →

Source: SEC EDGAR

accession 0001628280-22-028987

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.